Skip to main content
The Japanese Dental Science Review logoLink to The Japanese Dental Science Review
. 2022 Oct 28;58:336–347. doi: 10.1016/j.jdsr.2022.10.002

Macrophages in periodontitis: A dynamic shift between tissue destruction and repair

Linying Yin 1, Xinzhu Li 1,, Jin Hou 1,
PMCID: PMC9630779  PMID: 36340583

Abstract

Periodontitis is a chronic inflammatory disease associated with a dysbiotic bacterial biofilm in the subgingival environment that may disturb the balance between the oral microbiome and its host. The inability of the immune system to eliminate inflammation may result in the progressive destruction of tooth-support tissues. Macrophages are crucial cellular components of the innate immune system and play important roles in diverse physiological and pathological processes. In response to periodontitis-associated bacterial communities, macrophages contribute to inflammation and restoration of tissue homeostasis through pattern recognition receptor-induced signaling cascades; therefore, targeting macrophages can be a feasible strategy to treat patients with periodontitis. Although recent studies indicate that macrophages have a spectrum of activation states, ranging from pro-inflammatory to anti-inflammatory, the regulatory mechanism of the macrophage response to dysbiosis in a tissue-specific manner remains largely unclear. Herein, we attempt to summarize the potential role of macrophage activation in the progression of periodontitis, as well as its relevance to future approaches in the treatment of periodontitis.

Abbreviations: AIM2, absent in melanoma-2; CCL2, chemokine (C-C motif) ligand 2; CCR2, chemokine (C-C motif) receptor 2; DAMP, damage-associated molecular pattern; IFN, interferon; IL, interleukin; IRF, interferon regulatory factor; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; MLKL, mixed lineage kinase-like; MyD88, myeloid differentiation factor 88; NLR, nucleotide oligomerization domain-like receptor; PAMP, pathogen-associated molecular pattern; PRR, pattern recognition receptor; RANKL, receptor activator of nuclear factor kappa-B ligand; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumor necrosis factor; TRIF, Toll/IL-1R domain-containing adapter-inducing IFN-β

Keywords: Macrophages, Periodontitis, Dysbiosis, Oral microbiome, Inflammation

1. Introduction

Periodontitis is a multifactorial chronic inflammatory disease in the tooth-support tissues triggered by numerous pathogenic bacteria in the subgingival plaque, resulting in the progressive destruction of the periodontal ligament and alveolar bone [1], [2]. The subgingival plaque during periodontitis development has been well established by the qualitative and/or quantitative differences in the oral microbiota that transits from mainly Gram-positive to mainly obligately anaerobic Gram-negative bacteria [3], [4]. Several bacterial species play a crucial role in periodontitis pathogenesis due to their abundant virulence factors, including Porphyromonas gingivalis (P.gingivalis), Tannerella forsythia, Treponema denticola, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum (F. nucleatum) [5], [6], [7]. These key drivers can impact the host immune system and destroy the microenvironment for beneficial symbionts, leading to enhanced periodontitis development [8].

Innate immune signaling is crucial for the initial response to microbial pathogens. Compromised innate immunity reportedly increases the severity of periodontitis [9], [10]. However, an overactivated innate immune response results in increased inflammation and tissue injury. Damage to the periodontal ligament and alveolar bone stems from the immune system, as it attempts to destroy the microbes that disrupt the normal symbiosis between the oral tissues and the oral microbial community [11], [12]. The macrophage axis is an important cellular component of the innate immune response and plays a critical role in proper immune function. Macrophages are effector cells of innate immunity that phagocytose invading pathogens and secrete both pro-inflammatory and anti-inflammatory mediators [13], [14]. Additionally, macrophages can eliminate unwanted cellular material through programmed cell death, and link the innate response to adaptive immunity via antigen presentation [15], [16], [17]. Therefore, it is important to understand the mechanisms by which macrophages regulate immune homeostasis, inflammation, and pathogenesis.

Studies on macrophage activation and polarization in periodontitis have revealed their plasticity during the innate immune response. The expression of chemokine (C-X3-C motif) ligand 1/chemokine (C-X3-C motif) receptor 1 (CX3CL1/CX3CR1) and chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 (CCL2/CCR2) signaling pathways in response to different microenvironmental factors can promote macrophage recruitment, which mediates phenotypic and functional changes in macrophages in periodontitis and leads to tissue damage and repair [18], [19], [20], [21]. Moreover, macrophage activity can be increasingly dysregulated during aging, altering their phenotype and function in periodontal inflammation and tissue homeostasis, possibly explaining the high incidence of periodontitis in aging adults [22], [23]. Macrophage depletion during disease recovery in older mice can prevent increased inflammatory cytokine concentrations and bone loss [24]. Macrophages are master regulators of periodontal tissue homeostasis; they display remarkable plasticity, respond to danger signals, and adjust their phenotype and function according to the periodontal environment [25].

In this review, we describe the heterogeneity, activation, and multiple functions of macrophages in specific tissues, and their dynamic features in periodontitis. Deciphering the process of macrophage activation and polarization in periodontitis will shed some light on the development of new therapies to promote antimicrobial defense or inhibit inflammatory tissue destruction.

2. Macrophage origin, plasticity, and polarization

Over the past century, all macrophages have been considered a part of the mononuclear phagocyte system derived from committed hematopoietic stem cells located in the bone marrow [26]. Macrophage precursors are released into the peripheral blood as monocytes; they further migrate to tissues, and differentiate into macrophages or dendritic cells [27]. With the advancement of cellular and molecular technologies, several studies have demonstrated that many tissue-resident macrophage subpopulations arise from the yolk sac and fetal liver, and have the capacity for self-renewal at low levels throughout adult life to maintain themselves in the steady state independent of bone marrow-derived macrophage precursors [28], [29]. Along with the heterogeneous characteristics of tissue-resident macrophage populations, these cells can undergo rapid local proliferative expansion in response to environmental factors and initiate inflammatory and immune responses [30], [31], [32] (Fig. 1).

Fig. 1.

Fig. 1

Macrophage origin and plasticity. Tissue-resident macrophages arise from bone marrow-derived monocytes, yolk sac and fetal liver. These cells polarize into two major extreme states, M1 and M2, having pro-inflammatory and anti-inflammatory activities, respectively.

Tissue-resident periodontal macrophages are generally present in subgingival crevices or periodontal pockets and act as the first line of host defense against microbial dysbiosis [33], [34]. These cells are capable of secreting various effector molecules and can dynamically change their phenotype according to periodontal disease progression [35], [36], [37]. They also display great diversity in their morphologies, transcriptional profiles, and functional capabilities, largely dictated by their anatomical location [38]. However, the heterogeneity, functionality, and niche location of tissue-resident macrophages in the periodontium remain poorly defined.

Macrophage polarization in the periodontium has been studied using histological staining. Results revealed that these are the most plastic cells and are regulated by their surrounding microenvironment. These resident macrophages generally polarize into two major extremes upon stimulation: M1 and M2 [39], [40]. On the one hand, the classically activated M1 macrophages are considered a part of the cell-mediated immune response. They are also primed in response to lipopolysaccharide (LPS) or T helper type 1 cytokines, such as interferon (IFN)-γ [41]. These macrophages usually have an enhanced ability to secrete pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-6. TNF-α and IL-6 stimulate macrophage activation and the adaptive immune response, as well as regulating host defense and countering bacterial invasion through several mechanisms. However, excessive activation of M1 macrophages may result in persistent inflammation and tissue damage [42], [43], [44]. For instance, TNF-α expression modulates the alteration of tissue macrophage M1/M2 polarization leading to increased disease severity [45]. TNF-α blockade has been shown to inhibit M1 macrophage polarization and pro-inflammatory mediators, emerged as a probable therapy for reducing disease severity [46]. On the other hand, the alternatively activated M2 macrophages are generally polarized by Th2 cytokines, such as IL-4 and IL-13. The cytokines released by M2 macrophages include IL-10, arginase-1, and transforming growth factor (TGF), which have the function of inhibiting various inflammatory responses and promoting tissue repair; therefore, M2 macrophages are associated with anti-inflammatory action and immune regulation [47], [48], [49]. Therefore, these two macrophage subpopulations exhibit varied physiological properties.

Despite the differences between the two macrophage subpopulations, both exogenous and endogenous danger signals can alter macrophage polarization. Inflammation may alter macrophage phenotypes, which may contribute to disease progression and resolution [50]. Significantly, macrophage phenotype, both in vitro and in vivo, can be converted by the signal transducer and activator of transcription (STAT) family and interferon regulatory factor (IRF) [51], [52], [53]. Accumulating evidence has shown that M1 macrophage polarization can be regulated by nuclear factor kappa-B, STAT1, and IRF5 activation [54], [55], [56], whereas STAT3/STAT6, IRF4, and peroxisome proliferator-activated receptor-γ activation promote M2 macrophage polarization [52], [57], [58], [59], [60], [61]. Therefore, these findings provide a rationale for the treatment of inflammation by regulating macrophage polarization.

3. Macrophages as contributory factors in periodontal tissue destruction and repair

Macrophages are activated when pathogens are detected through recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The binding of these factors to pattern recognition receptors (PRRs) stimulates multiple signal transduction pathways, which ultimately alert the host to cell death and orchestrate the synthesis of various effector molecules [62]. Ideally, PRR responses, death signaling, and effector outputs coordinate immune responses against invading pathogens, which can ultimately contribute to periodontal tissue destruction and repair. Recent findings, as presented in this review, have highlighted that contradictory regulation of macrophages and their interactions with other cell types are responsible for both periodontal tissue damage and repair. The delicate balance between the oral microbial community and the host might be disrupted by either host immunoregulatory defects or an increase in the microbial challenge. Therefore, inflammation and dysbiosis can positively reinforce each other in a self-sustained feedforward loop [63], [64]. Alternatively, macrophages express various effector molecules required for tissue regeneration, such as TGF-β and IL-10, suggesting that the secretory actions of macrophages play important pro-reparative roles [65], [66]. Although macrophage-mediated tissue destruction and healing may occur simultaneously in human periodontitis, the inability to resolve inflammation drives extracellular matrix degradation and bone resorption [25], [67]. Herein, we integrated the current knowledge on immune sensing of macrophages contributing to periodontal tissue destruction and repair (Fig. 2).

Fig. 2.

Fig. 2

Macrophage cell death and cytokine production in periodontitis. Macrophages are activated when PRRs recognize PAMPs/DAMPs. The binding stimulates multiple signal transduction pathways: (A) Binding of PRRs activates NF-κB signaling and secretes various cytokines; (B) Binding of PRRs results in various forms of cell death, including pyroptosis, necroptosis, apoptosis and autophagy; ultimately leading to periodontal tissue destruction and repair. NF-κB: nuclear factor kappa-B; IκBα: NF-κB inhibitor α; dsDNA: double-stranded DNA; FADD: Fas-associated protein with death domain; TRADD: tumor necrosis factor receptor type 1-associated death domain; RIPK: receptor interacting protein kinase; GSDMD: gasdermin D; ATG: autophagy-related; LC3: microtubule-associated protein 1A/1B-light chain 3.

3.1. Macrophage PRRs

Macrophages are considered sentinels of the immune system because they ubiquitously express a multitude of PRRs that are in contact with the external environment and can thus recognize PAMPs from pathogens as well as DAMPs from apoptotic host cells and damaged senescent cells when present, and subsequently activate various intracellular signaling pathways [68], [69]. Currently, based on protein domain homology, these receptors can be divided into the following five types: toll-like receptors (TLRs), absent in melanoma-2 (AIM2)-like receptors, nucleotide oligomerization domain-like receptors (NLRs), retinoic acid-inducible gene-I-like receptors, and C-type lectin receptors. These five types of PRRs are widely present within the plasma membrane, intracellular compartment membranes, and macrophage cytoplasm [70], [71]. We focused on three types of PRRs identified in macrophages associated with periodontitis.

Activation of TLR2/TLR4/TLR9 signaling in macrophages plays a crucial role in triggering intracellular signaling cascades, mediated by the adaptor proteins namely, myeloid differentiation factor 88 (MyD88) and/or Toll/IL-1R domain-containing adapter-inducing IFN-β (TRIF), and subsequent activation of inflammatory responses [72], [73], [74]. TLR2 specifically recognizes fimbriae in combination with CD14 on the cell membrane of macrophages to activate two distinct signaling pathways, thereby mediating pro-inflammatory and pro-adhesive effects [75]. Activated TLR2 leads to nuclear factor kappa-B activation through the Toll-interleukin-1 receptor domain-containing adaptor protein/MyD88-dependent signaling pathway, thereby increasing the secretion of pro-inflammatory molecules [73], [75]. Induction of TLR2 inside-out signaling proceeds through Rac1, phosphoinositide-3-kinase, and cytohesin-1 upregulation of the high-affinity conformation of complement receptor 3, which is associated with increased intracellular persistence [76], [77]. In addition to binding to fimbriae, TLR2 is involved in the recognition of lipoprotein and P.gingivalis LPS [78], [79]. The recognition of LPS by TLR4 triggers the activation of two different signaling pathways. First, the MyD88-dependent pathway, resulting in the activation of C and c-Jun N-terminal kinase, required for the expression of CCL2 and macrophage inflammatory protein 1. Second, the MyD88-independent pathway, leading to the activation of the IFN-β/STAT1 signaling pathway via P38 mitogen-activated protein kinase and c-Jun N-terminal kinase, essential for IFN-γ-inducible 10 kDa protein (IP-10) production [80], [81]. Interestingly, macrophages of differential states may respond distinctively to virulence factors, such as LPS-tolerant macrophages, which respond through the excessive production of TNF and the decreased secretion of IL-1β [82]. TLR9 binding periodontitis-associated bacterial DNA initiates inflammation. TLR9 signaling can mediate periodontal bone loss by upregulating levels of IL-6, TNF, and receptor activator of nuclear factor kappa-B ligand (RANKL) [74]. Furthermore, the overproduction of nitric oxide is reportedly due to the destruction of periodontal health [83]. TLR9 is involved in the regulation of inducible nitric oxide synthase expression and nitric oxide secretion in P. gingivalis LPS-treated macrophages [84]. Notably, it has been reported that TLR9 may initiate a cascade of signals through interaction with other innate sensors, including TLR2 and TLR4. However, the underlying mechanism remains unknown [74].

In addition to TLRs, NLR inflammasomes are a subset of PRRs located in the cytoplasm that are associated with the occurrence and development of periodontitis. The NLRP3 inflammasome is the best-characterized component that consists of the cytoplasmic sensor NLRP3, adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and effector protein procaspase-1 [85], [86]. NLRP3 signaling is crucial for orchestrating microbial crosstalk with macrophages, because it can induce pyroptosis through the formation of plasma membrane pores and conversion of pro-IL-1β and pro-IL-18 into mature ligands, which are the key molecules for the integrity of tissue homeostasis and bacterial colonization [85], [87], [88]. NLRP3 also regulates alveolar bone loss in periodontitis, followed by significant upregulation of caspase-1, IL-1β and IL-18, resulting in a large number of inflammatory cell recruitment and promoting osteoclastic differentiation [89], [90]. Ablation of NLRP3 can result in a switch in the polarization of microglia toward an anti-inflammatory and M2 phenotype, displaying enhanced tissue remodeling [91]. Together, the regulation of the NLRP3 inflammasome might emerge as an effective strategy to modify periodontal inflammatory changes [92].

AIM2-like receptors are intracellular PRRs that recognize and bind to cytosolic double-stranded DNA [93]. The N-terminal pyrin domain of AIM2 binds to the ASC, which recruits caspase-1 through its caspase recruitment domain, thereby stimulating inflammasome formation and inducing the maturation and release of IL-1β and IL-18 [94]. Patients with periodontitis display upregulated AIM2 inflammasome, which releases IL-1β, promotes bone resorption, and induces tissue-degrading proteinase production [95], [96], [97].

3.2. Macrophage cell death

Upon stimulation with PAMPs/DAMPs, PRR-induced signal transduction pathways ultimately result in immune activation of the host to increase phagocytosis and pro-inflammatory cytokine secretion, and induce cell death. Regulated cell death is a genetically encoded process that can be activated not only in the context of physiological states but also as a consequence of microenvironmental disruption, and plays a role in key processes that might lead to the initiation, amplification, or chronicity of inflammatory signaling [98], [99]. Here, we briefly discuss the mechanisms that govern PRR-induced regulation of cell death in macrophages and their participation in the development of periodontitis.

Pyroptosis is a highly inflammatory form of cell lysis that regulates cell death. It can be initiated by the interaction of microbial components with PRRs that allows inflammasome activation, resulting in the massive release of cytosolic contents [88], [100]. Further, a large number of PAMPs and DAMPs are released from necrotic cells. These PAMPs and DAMPs can trigger a cascade of inflammatory responses from the neighboring cells (such as immune cells, epithelial cells and fibroblasts). Pyroptosis in macrophages infected with periodontal pathogens is dependent on the cleavage of gasdermin D by inflammatory caspases, including caspase-1 or caspase-11, -4, and -5, resulting in subsequent activation of the inflammatory response [85], [87], [88]. A recent report on Salmonella typhimurium-infected mice demonstrated that macrophages mediate crucial innate immune responses to intracellular bacteria via caspase-1-induced pyroptosis. With the lytic death of macrophages, pathogens are released into the extracellular space and become exposed to uptake and efficient killing by neutrophils through the activity of reactive oxygen species [101]. In addition, increased staining of gasdermin D was observed in human periodontitis tissues, implying that the pyroptotic cell death correlate with periodontitis severity [102]. In a mouse model of diabetes-associated periodontitis, NLRP3-mediated pyroptosis in macrophages plays a pivotal role in further impairing macrophage function and aggravating periodontal tissue injury [103]. One study shows that miR-155 expression can influence macrophage pyroptosis and the ability to engulf pathogens through regulating the NLRP3 inflammasome. Excessive uncontrolled pyroptosis in macrophage may contribute to the severe inflammatory response and tissue damage via the generation of multiple proinflammatory cytokines in vivo, including TNF-α and IL-6, which can promote osteoclast differentiation and activation, resulting in alveolar bone resorption [104]. Furthermore, there is a bidirectional crosstalk between apoptosis and pyroptosis. In gasdermin D low/null cell types, caspase-1 induces apoptotic cell death by activating caspase-3/7 [105]. Together, these studies contribute to the view that macrophage pyroptosis can eliminate intracellular microbes and increase pro-inflammatory molecules that appear to coordinate cellular repair, although the regulatory mechanism of macrophage pyroptosis in periodontitis warrants further investigation.

Necroptosis is another form of inflammatory cell death that can be triggered by different PRRs, such as TLR3, TLR4, and retinoic acid-inducible gene-I [69]. Activation of necroptosis induces the release of DAMPs, which is dependent on the activation of receptor-interacting protein kinase-3 and the phosphorylation of its substrate, mixed lineage kinase-like (MLKL), which drives the amplification and chronicity of inflammation and contributes to inflammation-induced tissue damage [106], [107], [108]. Moreover, positive staining was detected for phosphorylated MLKL in the periodontal supporting structure. Phosphorylated MLKL has been identified as a biomarker of necroptosis, suggesting that necroptosis contributes to P. gingivalis-induced periodontitis [109], [110]. However, evidence that macrophage necroptosis has detrimental effects on human periodontitis remains limited. A recent report based on a mouse model suggested that MLKL-mediated necroptosis accelerates periodontitis progression induced by P. gingivalis LPS. Upregulation of inflammatory cytokines at the mRNA level was detected in bone marrow-derived macrophages, and MLKL deficiency led to decreased bone resorption and attenuated osteoclast activation, indicating that MLKL-induced necroptosis in macrophages is a critical event that amplifies inflammation and contributes to disease pathology [111]. Although these studies indicate that macrophage necroptosis may be involved in tissue destruction in periodontitis, more studies using definite molecular markers of necroptosis and macrophages are required to establish the potential role of macrophage necroptosis in the pathogenesis of periodontitis.

Apoptosis is a genetically encoded death process in multicellular organisms that may have an anti-inflammatory effect on host defenses against pathogens [112], [113]. Apoptosis induction consists of two major pathways: an extrinsic pathway initiated by death receptors and an intrinsic pathway involving mitochondria [114]. Not surprisingly, PRR stimulation (TLR2 and TLR4) promotes apoptosis in macrophages through a MyD88/TRIF downstream signaling pathway that converges on effector caspase-3 activation. The clearance of apoptotic cells resolves inflammation, and is dependent on the formation of apoptotic bodies before the contents spill out of the dying cells, which would cause inflammation in the surrounding tissue [98], [114], [115], [116]. Several periodontal bacteria, such as Aggregatibacter actinomycetemcomitans and F. nucleatum, have been shown to cause apoptosis in macrophages. Intracellular F. nucleatum can inhibit macrophage apoptosis through activation of the phosphoinositide-3-kinase/Akt and extracellular-signal-regulated kinase signaling pathways, implying that macrophage apoptosis participates in the dissemination of bacterial infection during periodontitis [117], [118], [119]. Although the main function of macrophage apoptosis in periodontitis is often less defined, apoptosis of infected macrophages plays an essential role in the elimination of many intracellular bacteria, including Mycobacterium tuberculosis, which enters macrophages with the aid of major virulence factors [120]. Studies indicate that the success of the initial infection by M. tuberculosis relies on the ability of the pathogen to inhibit activation of the extrinsic apoptotic pathway in host macrophages. If apoptosis is dominant, the infection may cease and potentially be cleared. In contrast, if virulent bacteria successfully inhibit caspase-mediated apoptosis of their host cells, their increased number contributes to the rapid development of macrophage necrosis [121], [122]. It is unclear whether similar mechanisms exist in macrophages infected with periodontal pathogens.

Infected macrophages also undergo autophagy, a major intracellular degradation process that forms double-membrane vesicles termed autophagosomes and drives the sequestration and degradation of cytoplasmic material in the lysosome [123]. Recently, many studies have broadened autophagy to include an antibacterial outcome of TLR responses to PAMPs [124], [125]. TLR4 can induce autophagy in RAW264.7 macrophages upon stimulation with bacterial LPS, dependent on TRIF, receptor-interacting protein 1, and p38 mitogen-activated protein kinase signaling [126]. Moreover, the levels of Beclin-1, autophagy-related protein 5, and microtubule-associated protein 1A/1B-light chain 3-II, which are the specific markers of autophagy, increased in macrophages infected with P. gingivalis or Aggregatibacter actinomycetemcomitans, suggesting that macrophage autophagy contributes to the pathology of periodontitis. Activation of autophagy not only promotes bacterial clearance, but also limits NLRP3 and AIM2 inflammasome activity, thereby inhibiting IL-1β production [127]. Conversely, deletion of autophagic proteins promotes the activation of caspase-1 and secretion of IL-1β and IL-18, demonstrating that inflammasome-autophagy crosstalk in macrophages is critically linked to the severity of inflammation. Autophagic protein-depleted macrophages may enhance mitochondrial reactive oxygen species production by destroying mitochondrial integrity [128], [129]. Hence, impaired autophagy has been proposed to be responsible for poor outcomes in periodontitis, and the regulation of autophagy can function as an effective way to alleviate inflammation by eliminating active inflammasomes [130].

3.3. Macrophage-derived effector molecules

The relationship between effector molecules and periodontitis is complicated, but several key factors require attention because they always coexist with periodontitis. Various effector molecules are released by macrophages and involved in the host defense against infection. To understand the destruction and repair mechanisms underlying periodontitis, it is important to understand the role of effector molecules, including chemokines, pro-inflammatory cytokines, and anti-inflammatory cytokines.

The pro-inflammatory mediators predominantly derived from activated macrophages accumulate and probably contribute to chronic inflammation. Evidence shows a correlation between macrophage-derived effector molecules and tissue destruction during periodontitis (Table 1). For instance, major chemokines, including CCL2, macrophage inflammatory protein 1α, and macrophage migration inhibitory factor, are characterized by pro-inflammatory and chemotactic responses, and their expression is increased in periodontitis, leading to periodontal tissue damage [131], [132], [133]. CCL2 downregulation can alleviate alveolar bone loss and rescue epithelial lesions by suppressing periodontal inflammation [21], [134]. Additionally, the production of prostaglandin E2, which contributes to the destruction of the extracellular matrix in periodontal lesions, is generally upregulated in macrophages and is associated with increased cyclooxygenase 2 activity [135], [136].

Table 1.

Characteristics of macrophage-derived biomarkers in periodontitis.

Marker Inflammation Mechanism & notes References
IFN-γ Pro- Activates M1 macrophages to promote periodontal bone loss [39], [181]
IL-6 Pro- Promotes periodontal tissue damage [39], [181]
IL-4 Anti- Activates M2 macrophages to regulate inflammation [49]
IL-10 Anti- Inhibits osteoclastogenesis and stimulates osteoblastic differentiation [66]
RANKL Pro- Promotes periodontal bone loss [74]
TNF-α Pro- Promotes periodontal bone loss [139], [140], [141]
MMP-9 Pro- Promotes extracellular matrix degradation and alveolar bone resorption [149]
MMP-13 Pro- Promotes periodontal bone loss [150]
CCL2 Pro- Recruits macrophages to the site of infection and induces alveolar bone loss and epithelial lesions [131], [160]
CX3CR1 Anti- /pro- Regulates inflammation and induces bacterial survival and bone resorption [160], [170]
TGF-β Anti- Enhances the production and deposition of extracellular matrix and suppresses the expression of pro-inflammatory cytokines [162], [163], [164]
Cystatin C Anti- Promotes bone regeneration by regulating osteoblasts and osteoclasts [180]

Production of TNF superfamily members, especially TNF-α and RANKL, is intricately involved in the pathology of periodontitis. TLRs induce the production of TNF-α from macrophages, which not only activates macrophages but also triggers stronger activation of the nuclear factor kappa-B pathway [73], [75]. Furthermore, TNF-α can form an autocrine loop that sustains the expression of inflammatory genes and induces delayed expression of interferon-response genes, as well as enhances macrophage responses to subsequent stimulation of cytokines and TLRs. This TNF-dependent feedforward loop plays an important role in sustaining inflammation [137]. Recent clinical study demonstrates that elevated serum levels of TNF-α in patients with periodontitis may also contribute to B-cell response and associate with periodontitis disease severity [138]. Besides its immunoregulatory functions, the proinflammatory cytokine TNF-α may also exhibit an important role in bone metabolism and inflammatory bone diseases. TNF-α appears to contribute to inflammatory bone loss by promoting osteoclast differentiation with RANKL and mediating osteoblast apoptosis [139], [140], [141]. Moreover, patients with periodontitis exhibit significantly higher RANKL levels than healthy individuals and an increased ratio of RANKL to its inhibitor, osteoprotegerin [142], [143]. Systemic administration of osteoprotegerin can suppress osteoclast formation by inhibiting the RANKL/RANK interaction, thereby alleviating alveolar bone resorption in an experimental ligature-induced periodontitis in rats[144]. Furthermore, TNF shares many biologic properties with IL-1 family. Blockade of IL-1 and TNF activities in mouse models could suppress inflammatory cell infiltration and inhibit osteoclast formation during periodontal bone resorption [145]. Therefore, the TNF superfamily has direct damaging effects on the periodontal tissues of patients with periodontitis.

Matrix metalloproteinases (MMPs) are pro-inflammatory mediators that belong to the most prominent and widely studied proteinase family associated with periodontal diseases. They may play a significant role as drivers of destructive inflammation, causing periodontal destruction by degrading the extracellular matrix and regulating tissue remodeling [146]. In vitro experiments showed that F. nucleatum and Treponema denticola, which are leading pathogens in chronic periodontitis, can upregulate the secretion of MMP-9 in macrophages [147], [148]. These increased levels of MMP-9 have pro-inflammatory effects in destructive periodontal diseases, including degradation of the extracellular matrix and basement membrane components and resorption of alveolar bone [149]. MMP-13 immunoreactivity was identified in macrophage-like cells of patients with periodontitis, which may also potentiate bone resorption [150]. MMP-13 has been implicated in the generation of collagen fragments that activate osteoclasts and proMMP-9 in vitro [151], [152]. In turn, active MMP-9 released by osteoclasts further digests denatured collagen derived from MMP-13 activity, leading to pre-osteoclast recruitment to sites for osteoclast differentiation and bone loss [151], [153]. Accordingly, it appears that MMP-13 and -9 form a positive feedback loop to perpetuate periodontal soft- and hard-tissue destruction in vivo. These results may be useful for macrophage-targeted drug development in future [153]. Furthermore, tissue fibrosis observed in periodontitis contributes to dysregulation of periodontal homeostasis [154]. Recent studies based on liver fibrosis models have suggested that hepatic macrophages can express several MMPs, including MMP-9, MMP-12, and MMP-13, which function in matrix degradation and thus favor the resolution of liver injury and fibrosis [155], [156], [157]. However, the mechanisms by which macrophage-derived MMPs act as key regulators of periodontal fibrosis are not yet fully understood.

Recent studies have shown that tissue repair in inflammation not only depends on the clearance of virulence factors but also on the capacity of the remaining cells to boost tissue regeneration and remodeling [158], [159]. Macrophages perform timely removal of cell debris and pathogens, and participate in extracellular matrix deposition and bone formation in periodontitis [50], [160]. Macrophage depletion during distinct phases of mouse skin repair demonstrates that macrophages exert specific functions at different stages and facilitate tissue homeostasis [161]. Therefore, alterations in the secretion of anti-inflammatory factors by macrophages may significantly contribute to modulating and defining the process of periodontal tissue repair.

The production of TGF-β, a member of a family of dimeric polypeptide growth factors, has been associated with inflammation resolution [162]. Recent studies have identified that TGF-β can suppress the expression of pro-inflammatory cytokines and contribute to the induction of LPS tolerance [163], [164], [165]. Impairment of TGF-β signaling in macrophages results in increased severity of intestinal inflammation during the resolution phase [166]. Moreover, TGF-β regulates various cellular processes, such as cell proliferation, differentiation, and migration, and affects the production and deposition of extracellular matrix [162]. In a model of pulmonary inflammation and fibrosis, upregulation of TGF-β derived from alveolar macrophages was detected, which may be associated with inflammation suppression and stimulation of collagen production to resolve lesions [167], [168], [169]. Although these studies indicate that TGF-β is indispensable for tissue regeneration and remodeling in human diseases, further studies are required to establish the involvement of macrophage-derived TGF-β in the pathogenesis of human periodontitis.

The chemokine receptor CX3CR1 acts as a critical regulator of tissue homeostasis and periodontitis pathogenesis by modulating the inflammatory response of macrophages. The upregulated level of CX3CR1, binding to the chemokine CX3CL1, correlates with leucocytes migration into the inflamed periodontal tissue [19]. While some studies have revealed that CX3CR1 accounts for bacterial survival and bone resorption, most studies corroborate that CX3CR1 is required for the resolution of inflammation in periodontitis [160], [170]. Decreased CX3CR1 expression in macrophages has been linked to elevated and persistent inflammation [171]. By using a DSS-induced colitis model in mice, the CX3CR1/ CX3CL1 axis has been demonstrated that contributes to macrophage anti-inflammatory activities for maintaining intestinal homeostasis and induces the production of anti-inflammatory cytokines such as IL-10 [172]. However, how CX3CR1-expressing macrophage regulate the process of periodontal tissue repair remains to be confirmed. Interestingly, the production of the anti-inflammatory cytokine IL-10 is significantly increased in macrophages infected with periodontal pathogens that could inhibit osteoclastogenesis and stimulate osteoblastic differentiation [66]. Recent research based on mice models suggests that induction of IL-10 may negatively regulate IL-17-mediated periodontitis. IL-10 deficient mice develop an elevated level of IL-17 in the ligation model and stimulate macrophage into M1 phenotype in the gingival tissue, which contributes to alveolar bone loss [173]. IL-10 also prevents the metabolic switch to glycolysis in LPS-stimulated macrophages and suppresses the accumulation of dysfunctional mitochondria, which are usually cleared by autophagy [174].

4. Macrophages as therapeutic targets in periodontitis

Currently, strategies have been developed to target tissue-resident macrophages and improve disease pathology, including tumors, liver diseases, and central nervous system diseases [175]. However, to date no agent designed to manipulate macrophage reprogramming in the inflammatory microenvironment has been tested to treat periodontitis. Despite these cellular dynamics and plasticity, given the consensus that macrophages play an important role in tissue damage and repair, the mechanisms described above may provide possible macrophage-targeting therapies. Herein, we discuss several potential therapeutic methods targeting macrophages to inhibit their inflammatory response and promote tissue repair in periodontitis.

4.1. Targeting macrophage polarization

The M1/M2 concept is well known for its opposing effects in periodontitis, mediating dynamic changes between pro-inflammatory and anti-inflammatory responses (Fig. 3). Depending on the periodontal microenvironment, while unactivated macrophages can initially drive the polarization of pro-inflammatory M1 macrophages under the stimulation of periodontal microbes and their products, M1 macrophages can reprogram their phenotypes toward anti-inflammatory M2 macrophages in the presence of IL-4, resulting in conversion of the overall environment [176]. Additionally, given the complex functioning of macrophages, there is an increasing concern that phenotypic switching from M1 to M2 macrophages during the transition from acute to chronic inflammatory conditions would protect an overwhelming and uncontrolled immune response [177], [178].

Fig. 3.

Fig. 3

The dynamic changes in macrophage polarization and functions in tissue damage and repair during periodontitis progression. Depending on the periodontal microenvironment: non-activated macrophages can initially drive the polarization of pro-inflammatory M1 macrophages under the stimulation of periodontal microbes and their products; M1 macrophages release TNF-α and MMPs leading to tissue damage; M1 macrophages can reprogram their phenotypes toward anti-inflammatory M2 macrophages in the presence of IL-4 or IL-13; M2 macrophages secrete IL-10 and TGF-β leading to tissue regeneration and conversion of the overall environment. Th: T helper cells.

The specific inhibition M1 pro-inflammatory effect is a possible therapeutic strategy. Several studies have indicated that a higher ratio of M1 macrophages plays an important role in the initiation and maintenance of the inflammatory state during chronic periodontitis, which may cause or reflect tissue damage, and is positively correlated with clinical probing depth [25], [40], [179]. Notably, many M1-related cytokines and proteinases, such as IFN-γ, IL-6, and MMP-9, have been shown to promote alveolar bone loss and aggravate periodontitis [39], [180], [181], [182]. Therefore, this strategy can be potentially implemented for targeting M1 macrophages in periodontitis immunotherapy, limiting the catabolic and pro-inflammatory activities of these cells. One example is the use of bindarit, a CCL2 synthesis inhibitor, which can suppress the infiltration of pro-inflammatory monocytes and alter the inflammatory properties of macrophages, leading to decreased production of inflammatory cytokines and MMPs by macrophages in the inflamed periodontium under diabetic conditions, thus improving the periodontal microenvironment [21]. Together, these findings emphasize the need for future research to determine whether M1 macrophages can promote inflammation and destroy tissues while simultaneously maintaining innate immune function.

Another approach is to repolarize M1 macrophages to M2 macrophages, in which the interactions between macrophages and T cells are central not only for suppressing osteolytic activity but also for triggering the repair process. M2 macrophages are responsible for enhanced anti-inflammatory activity mediated by the production of anti-inflammatory molecules, migration of aged neutrophils, and phagocytosis by macrophages. However, M2 macrophages also secrete cystatin C, which promotes bone regeneration through osteoblast and osteoclast regulation [176], [180]. In general, M2 macrophages are crucial for bridging the gap between inflammatory regression and tissue repair. It has been demonstrated that injecting M2 macrophages into murine periodontal tissues increases the ratio of regulatory T cells, resulting in the inhibition of osteoclast activity [183]. Using a mouse model of stem cell transplantation, macrophage polarization toward the M2 phenotype has been demonstrated to enhance periodontal tissue regeneration in the early stages of tissue repair [184]. Notably, exosomes derived from gingival mesenchymal stem cells seem to promote M1 macrophage transformation into M2 macrophages, preventing the production of pro-inflammatory factors [185]. These results indicate that M2 macrophages may be crucial to decrease inflammatory injury or stimulate tissue repair. Despite the anabolic and anti-inflammatory functions of M2 macrophages, the mechanisms by which M1 macrophages convert their phenotype to M2 in periodontitis require further investigation.

4.2. Modulating macrophage PRRs

The mechanisms outlined above suggest that the highly sensitive recognition of PRRs by PAMPs/DAMPs acts as a double-edged sword. On the one hand, it activates many intracellular signaling pathways to effectively clear pathogens and danger signals. On the other hand, it promotes the production of inflammatory molecules and produces an inflammatory microenvironment, thereby causing tissue damage [186], [187]. Given the important role of PRRs in stimulating both innate and acquired immunity in periodontitis, we propose that PRRs could serve as drug targets for inflammatory diseases and as important immune checkpoints for immunotherapy.

Modulation of PRRs may be another way to regulate macrophage function in periodontitis. TLRs and NLRs have been the most studied and characterized in the pathophysiology of some inflammatory diseases. Studies have revealed that TLR2 and TLR4 signaling are both predominantly required for the effective clearance of pathogens, and thus play crucial roles in infection-induced inflammation. Polymicrobe-infected TLR2-/- and TLR4-/- mice demonstrated that TLR deficiency could inhibit accelerated alveolar bone resorption, indicating the important role of TLR2 and TLR4 in periodontitis [188]. To date, several therapeutic strategies for targeting TLR signaling pathways have been recognized for modulating the host response [189]. In periodontitis, macrophages can be targeted with specific CXC-chemokine receptor 4 antagonists that promote the clearance of P. gingivalis by interfering with TLR2 activation [190]. Furthermore, the NLR family and the NLRP3 inflammasome are reportedly involved in various inflammatory diseases. Inhibition of NLRP3 inflammasome activation regulates inflammasome-mediated inflammation [191], [192]. MCC950, a selective inhibitor of the NLRP3 inflammasome, has been developed to treat periodontitis and can reduce alveolar bone loss by inhibiting osteoclast differentiation in ligation-induced periodontitis [89]. MCC950 also suppressed the inflammatory response in THP-1 cell line macrophage-like cells induced by periodontal bacteria [193]. Taken together, the effects of macrophage PRRs on periodontitis appear to be complex and remain to be demonstrated.

5. Conclusions and perspectives

In this review, we outlined the relationship between macrophage activation and periodontitis progression. Macrophages have high plasticity that allows them to respond efficiently to various environmental stimuli and shift their phenotypes. The physiological characterization of macrophages may contribute to homeostatic processes and host defense in a tissue-specific manner. Macrophages perform important functions in periodontitis during the innate immune response to dysbiotic bacterial biofilms and initiation of inflammation. In addition to their tissue destructive effects, macrophages can act as key regulators of tissue homeostasis and repair. Consequently, it is important to appreciate macrophage heterogeneity and evolution during periodontal tissue damage and repair. It is also pertinent to recognize that most studies on macrophage activation have been performed in vitro using microbial agonists or cytokines to stimulate cells and measure the effector cytokine production and changes in gene expression. Therefore, harnessing the host’s immune system to control and prevent periodontitis requires a more comprehensive characterization of macrophage activation in human patients.

Macrophage activation is a multidimensional occurrence in response to integrated signals from a specific microenvironment [194]. However, many aspects of macrophage biology in inflammation remain unresolved, as the M1/M2 paradigm does not fully represent the situation in vivo. For example, the M1/M2 paradigm does not pay sufficient attention to cell origins, tissue microenvironment, and time. When tissue-resident macrophages coexist with monocyte-derived macrophages during infection and tissue injury, they are influenced by a combination of ontogeny and dynamic tissue microenvironments [195], [196]. Furthermore, identifying macrophage functions based on stimuli does not adequately reflect immune conditions. Since there is a nearly infinite combination of stimuli, each of the combination can develop different population of macrophages [195]. Finally, the transcriptome of human monocyte-derived macrophages activated by different in vitro stimuli or combinations of stimuli associated with chronic inflammation revealed a spectrum model of macrophage activation rather than M1/M2 polarization [197]. Therefore, it is necessary to realize that the M1 or M2 phenotype is an oversimplification that insufficiently describes macrophage activation during disease progression. The ability to define a standard naming convention for macrophages based on their morphology and function is becoming one of the most important tasks. In addition, the extension of macrophage activation from M1/M2 polarization to a spectrum model brings a new perspective to explore their functions in chronic inflammation and contributes to improving therapeutic strategies targeting specific macrophage subsets. Therefore, a deeper understanding of macrophage tissue-specific functions will help elucidate the signaling pathways and mechanisms driving periodontal tissue destruction and repair, provide potential therapeutic strategies for the treatment of periodontitis. Besides, this information will enhance our overall understanding of inflammation and immune system.

Declaration of Competing Interest

None.

Acknowledgment

This work was supported by the National Natural Science Foundation of China (Grant NO. 81971902).

Contributor Information

Xinzhu Li, Email: lixinzhu880623@i.smu.edu.cn.

Jin Hou, Email: houjin@smu.edu.cn.

References

  • 1.Belstrøm D., Grande M.A., Sembler-Møller M.L., Kirkby N., Cotton S.L., Paster B.J., et al. Influence of periodontal treatment on subgingival and salivary microbiotas. J Periodontol. 2018;89:531–539. doi: 10.1002/JPER.17-0377. [DOI] [PubMed] [Google Scholar]
  • 2.Caton J.G., Armitage G., Berglundh T., Chapple I.L.C., Jepsen S., Kornman K.S., et al. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Clin Periodontol. 2018;45(Suppl 20):S1–S8. doi: 10.1111/jcpe.12935. [DOI] [PubMed] [Google Scholar]
  • 3.Meuric V., Le Gall-David S., Boyer E., Acuña-Amador L., Martin B., Fong S.B., et al. Signature of microbial dysbiosis in periodontitis. Appl Environ Microbiol. 2017:83. doi: 10.1128/AEM.00462-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Marsh P.D. Microbial ecology of dental plaque and its significance in health and disease. Adv Dent Res. 1994;8:263–271. doi: 10.1177/08959374940080022001. [DOI] [PubMed] [Google Scholar]
  • 5.Socransky S.S., Haffajee A.D., Cugini M.A., Smith C., Kent R.L., Jr. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25:134–144. doi: 10.1111/j.1600-051x.1998.tb02419.x. [DOI] [PubMed] [Google Scholar]
  • 6.Deng Z.L., Szafrański S.P., Jarek M., Bhuju S., Wagner-Döbler I. Dysbiosis in chronic periodontitis: key microbial players and interactions with the human host. Sci Rep. 2017;7:3703. doi: 10.1038/s41598-017-03804-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ng H.M., Kin L.X., Dashper S.G., Slakeski N., Butler C.A., Reynolds E.C. Bacterial interactions in pathogenic subgingival plaque. Microb Pathog. 2016;94:60–69. doi: 10.1016/j.micpath.2015.10.022. [DOI] [PubMed] [Google Scholar]
  • 8.Sima C., Glogauer M. Macrophage subsets and osteoimmunology: tuning of the immunological recognition and effector systems that maintain alveolar bone. Periodontol 2000. 2013;63:80–101. doi: 10.1111/prd.12032. [DOI] [PubMed] [Google Scholar]
  • 9.Fine N., Hassanpour S., Borenstein A., Sima C., Oveisi M., Scholey J., et al. Distinct oral neutrophil subsets define health and periodontal disease states. J Dent Res. 2016;95:931–938. doi: 10.1177/0022034516645564. [DOI] [PubMed] [Google Scholar]
  • 10.Chukkapalli S.S., Ambadapadi S., Varkoly K., Jiron J., Aguirre J.I., Bhattacharyya I., et al. Impaired innate immune signaling due to combined Toll-like receptor 2 and 4 deficiency affects both periodontitis and atherosclerosis in response to polybacterial infection. Pathog Dis. 2018:76. doi: 10.1093/femspd/fty076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Duran-Pinedo A.E., Chen T., Teles R., Starr J.R., Wang X., Krishnan K., et al. Community-wide transcriptome of the oral microbiome in subjects with and without periodontitis. ISME J. 2014;8:1659–1672. doi: 10.1038/ismej.2014.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Abusleme L., Dupuy A.K., Dutzan N., Silva N., Burleson J.A., Strausbaugh L.D., et al. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J. 2013;7:1016–1025. doi: 10.1038/ismej.2012.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu D., Weng Y., Feng Y., Liang B., Wang H., Li L., et al. Trem1 induces periodontal inflammation via regulating M1 polarization. J Dent Res. 2022;101:437–447. doi: 10.1177/00220345211044681. [DOI] [PubMed] [Google Scholar]
  • 14.Wang H., Peng W., Zhang G., Jiang M., Zhao J., Zhao X., et al. Role of PG0192 and PG0193 in the modulation of pro-inflammatory cytokines in macrophages in response to Porphyromonas gingivalis. Eur J Oral Sci. 2022;130 doi: 10.1111/eos.12851. [DOI] [PubMed] [Google Scholar]
  • 15.Stutz M.D., Allison C.C., Ojaimi S., Preston S.P., Doerflinger M., Arandjelovic P., et al. Macrophage and neutrophil death programs differentially confer resistance to tuberculosis. Immunity. 2021;54 doi: 10.1016/j.immuni.2021.06.009. 1758-71.e7. [DOI] [PubMed] [Google Scholar]
  • 16.Qu Z., Zhou J., Zhou Y., Xie Y., Jiang Y., Wu J., et al. Mycobacterial EST12 activates a RACK1-NLRP3-gasdermin D pyroptosis-IL-1β immune pathway. Sci Adv. 2020:6. doi: 10.1126/sciadv.aba4733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Balbo P., Silvestri M., Rossi G.A., Crimi E., Burastero S.E. Differential role of CD80 and CD86 on alveolar macrophages in the presentation of allergen to T lymphocytes in asthma. Clin Exp Allergy. 2001;31:625–636. doi: 10.1046/j.1365-2222.2001.01068.x. [DOI] [PubMed] [Google Scholar]
  • 18.Zaid A., Tharmarajah K., Mostafavi H., Freitas J.R., Sheng K.C., Foo S.S., et al. Modulation of monocyte-driven myositis in alphavirus infection reveals a role for CX(3)CR1(+) macrophages in tissue repair. mBio. 2020:11. doi: 10.1128/mBio.03353-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hosokawa Y., Nakanishi T., Yamaguchi D., Nakae H., Matsuo T. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Clin Exp Immunol. 2005;139:506–512. doi: 10.1111/j.1365-2249.2005.02675.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Boniakowski A.E., Kimball A.S., Joshi A., Schaller M., Davis F.M., denDekker A., et al. Murine macrophage chemokine receptor CCR2 plays a crucial role in macrophage recruitment and regulated inflammation in wound healing. Eur J Immunol. 2018;48:1445–1455. doi: 10.1002/eji.201747400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shen Z., Kuang S., Zhang M., Huang X., Chen J., Guan M., et al. Inhibition of CCL2 by bindarit alleviates diabetes-associated periodontitis by suppressing inflammatory monocyte infiltration and altering macrophage properties. Cell Mol Immunol. 2021;18:2224–2235. doi: 10.1038/s41423-020-0500-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Zhang Z., Schlamp F., Huang L., Clark H., Brayboy L. Inflammaging is associated with shifted macrophage ontogeny and polarization in the aging mouse ovary. Reproduction. 2020;159:325–337. doi: 10.1530/REP-19-0330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gonzalez O.A., Novak M.J., Kirakodu S., Stromberg A., Nagarajan R., Huang C.B., et al. Differential gene expression profiles reflecting macrophage polarization in aging and periodontitis gingival tissues. Immunol Invest. 2015;44:643–664. doi: 10.3109/08820139.2015.1070269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Clark D., Halpern B., Miclau T., Nakamura M., Kapila Y., Marcucio R. The contribution of macrophages in old mice to periodontal disease. J Dent Res. 2021;100:1397–1404. doi: 10.1177/00220345211009463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Almubarak A., Tanagala K.K.K., Papapanou P.N., Lalla E., Momen-Heravi F. Disruption of monocyte and macrophage homeostasis in periodontitis. Front Immunol. 2020;11:330. doi: 10.3389/fimmu.2020.00330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.van Furth R., Cohn Z.A. The origin and kinetics of mononuclear phagocytes. J Exp Med. 1968;128:415–435. doi: 10.1084/jem.128.3.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317:666–670. doi: 10.1126/science.1142883. [DOI] [PubMed] [Google Scholar]
  • 28.Hoeffel G., Chen J., Lavin Y., Low D., Almeida F.F., See P., et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity. 2015;42:665–678. doi: 10.1016/j.immuni.2015.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bian Z., Gong Y., Huang T., Lee C.Z.W., Bian L., Bai Z., et al. Deciphering human macrophage development at single-cell resolution. Nature. 2020;582:571–576. doi: 10.1038/s41586-020-2316-7. [DOI] [PubMed] [Google Scholar]
  • 30.Jenkins S.J., Ruckerl D., Cook P.C., Jones L.H., Finkelman F.D., van Rooijen N., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332:1284–1288. doi: 10.1126/science.1204351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Davies L.C., Rosas M., Jenkins S.J., Liao C.T., Scurr M.J., Brombacher F., et al. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nat Commun. 2013;4:1886. doi: 10.1038/ncomms2877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ginhoux F., Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14:392–404. doi: 10.1038/nri3671. [DOI] [PubMed] [Google Scholar]
  • 33.Hassell T.M. Tissues and cells of the periodontium. Periodontol 2000. 1993;3 doi: 10.1111/j.1600-0757.1993.tb00230.x. [DOI] [PubMed] [Google Scholar]
  • 34.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Charon J., Toto P.D., Gargiulo A.W. Activated macrophages in human periodontitis. J Periodontol. 1981;52:328–335. doi: 10.1902/jop.1981.52.6.328. [DOI] [PubMed] [Google Scholar]
  • 36.Davies P., Page R.C., Allison A.C. Changes in cellular enzyme levels and extracellular release of lysosomal acid hydrolases in macrophages exposed to group A streptococcal cell wall substance. J Exp Med. 1974;139:1262–1282. doi: 10.1084/jem.139.5.1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Huang C.B., Alimova Y., Ebersole J.L. Macrophage polarization in response to oral commensals and pathogens. Pathog Dis. 2016:74. doi: 10.1093/femspd/ftw011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mass E., Ballesteros I., Farlik M., Halbritter F., Günther P., Crozet L., et al. Specification of tissue-resident macrophages during organogenesis. Science. 2016:353. doi: 10.1126/science.aaf4238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhou L.N., Bi C.S., Gao L.N., An Y., Chen F., Chen F.M. Macrophage polarization in human gingival tissue in response to periodontal disease. Oral Dis. 2019;25:265–273. doi: 10.1111/odi.12983. [DOI] [PubMed] [Google Scholar]
  • 40.Zhang B., Yang Y., Yi J., Zhao Z., Ye R. Hyperglycemia modulates M1/M2 macrophage polarization via reactive oxygen species overproduction in ligature-induced periodontitis. J Periodontal Res. 2021;56:991–1005. doi: 10.1111/jre.12912. [DOI] [PubMed] [Google Scholar]
  • 41.Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303–7311. doi: 10.4049/jimmunol.177.10.7303. [DOI] [PubMed] [Google Scholar]
  • 42.Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–292. doi: 10.1084/jem.176.1.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Maasfeh L., Härtlova A., Isaksson S., Sundin J., Mavroudis G., Savolainen O., et al. Impaired luminal control of intestinal macrophage maturation in patients with ulcerative colitis during remission. Cell Mol Gastroenterol Hepatol. 2021;12:1415–1432. doi: 10.1016/j.jcmgh.2021.06.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nathan C.F. Secretory products of macrophages. J Clin Invest. 1987;79:319–326. doi: 10.1172/JCI112815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ait-Lounis A., Laraba-Djebari F. TNF-alpha modulates adipose macrophage polarization to M1 phenotype in response to scorpion venom. Inflamm Res. 2015;64:929–936. doi: 10.1007/s00011-015-0876-z. [DOI] [PubMed] [Google Scholar]
  • 46.Lin S.H., Chuang H.Y., Ho J.C., Lee C.H., Hsiao C.C. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J Dermatol Sci. 2018;91:276–284. doi: 10.1016/j.jdermsci.2018.05.009. [DOI] [PubMed] [Google Scholar]
  • 47.Doyle A.G., Herbein G., Montaner L.J., Minty A.J., Caput D., Ferrara P., et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol. 1994;24:1441–1445. doi: 10.1002/eji.1830240630. [DOI] [PubMed] [Google Scholar]
  • 48.Loke P., Gallagher I., Nair M.G., Zang X., Brombacher F., Mohrs M., et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol. 2007;179:3926–3936. doi: 10.4049/jimmunol.179.6.3926. [DOI] [PubMed] [Google Scholar]
  • 49.Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35. doi: 10.1038/nri978. [DOI] [PubMed] [Google Scholar]
  • 50.Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969. doi: 10.1038/nri2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lin C.C., Chen S.Y., Lien H.Y., Lin S.Z., Lee T.M. Targeting the PI3K/STAT3 axis modulates age-related differences in macrophage phenotype in rats with myocardial infarction. J Cell Mol Med. 2019;23:6378–6392. doi: 10.1111/jcmm.14526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11:936–944. doi: 10.1038/ni.1920. [DOI] [PubMed] [Google Scholar]
  • 53.Lacey D.C., Achuthan A., Fleetwood A.J., Dinh H., Roiniotis J., Scholz G.M., et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188:5752–5765. doi: 10.4049/jimmunol.1103426. [DOI] [PubMed] [Google Scholar]
  • 54.Liao X., Sharma N., Kapadia F., Zhou G., Lu Y., Hong H., et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest. 2011;121:2736–2749. doi: 10.1172/JCI45444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Leopold Wager C.M., Hole C.R., Wozniak K.L., Olszewski M.A., Mueller M., Wormley F.L., Jr. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Infect Immun. 2015;83:4513–4527. doi: 10.1128/IAI.00935-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12:231–238. doi: 10.1038/ni.1990. [DOI] [PubMed] [Google Scholar]
  • 57.O'Shea J.J., Pesu M., Borie D.C., Changelian P.S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004;3:555–564. doi: 10.1038/nrd1441. [DOI] [PubMed] [Google Scholar]
  • 58.Gong M., Zhuo X., Ma A. STAT6 upregulation promotes M2 macrophage polarization to suppress atherosclerosis. Med Sci Monit Basic Res. 2017;23:240–249. doi: 10.12659/MSMBR.904014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Szanto A., Balint B.L., Nagy Z.S., Barta E., Dezso B., Pap A., et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity. 2010;33:699–712. doi: 10.1016/j.immuni.2010.11.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–1120. doi: 10.1038/nature05894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555. doi: 10.1016/s1471-4906(02)02302-5. [DOI] [PubMed] [Google Scholar]
  • 62.Lin J., Bi L., Yu X., Kawai T., Taubman M.A., Shen B., et al. Porphyromonas gingivalis exacerbates ligature-induced, RANKL-dependent alveolar bone resorption via differential regulation of Toll-like receptor 2 (TLR2) and TLR4. Infect Immun. 2014;82:4127–4134. doi: 10.1128/IAI.02084-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Hajishengallis G., Lamont R.J. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 2012;27:409–419. doi: 10.1111/j.2041-1014.2012.00663.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015;15:30–44. doi: 10.1038/nri3785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Takaki H., Minoda Y., Koga K., Takaesu G., Yoshimura A., Kobayashi T. TGF-beta1 suppresses IFN-gamma-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Genes Cells. 2006;11:871–882. doi: 10.1111/j.1365-2443.2006.00988.x. [DOI] [PubMed] [Google Scholar]
  • 66.Zhang Q., Chen B., Yan F., Guo J., Zhu X., Ma S., et al. Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int. 2014;2014 doi: 10.1155/2014/284836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Yucel-Lindberg T., Båge T. Inflammatory mediators in the pathogenesis of periodontitis. Expert Rev Mol Med. 2013;15 doi: 10.1017/erm.2013.8. [DOI] [PubMed] [Google Scholar]
  • 68.Kumar V. Targeting macrophage immunometabolism: dawn in the darkness of sepsis. Int Immunopharmacol. 2018;58:173–185. doi: 10.1016/j.intimp.2018.03.005. [DOI] [PubMed] [Google Scholar]
  • 69.Amarante-Mendes G.P., Adjemian S., Branco L.M., Zanetti L.C., Weinlich R., Bortoluci K.R. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. doi: 10.3389/fimmu.2018.02379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Mortaz E., Adcock I.M., Tabarsi P., Darazam I.A., Movassaghi M., Garssen J., et al. Pattern recognitions receptors in immunodeficiency disorders. Eur J Pharm. 2017;808:49–56. doi: 10.1016/j.ejphar.2017.01.014. [DOI] [PubMed] [Google Scholar]
  • 71.Li D., Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6:291. doi: 10.1038/s41392-021-00687-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Nussbaum G., Ben-Adi S., Genzler T., Sela M., Rosen G. Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath components. Infect Immun. 2009;77:3939–3947. doi: 10.1128/IAI.00488-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Papadopoulos G., Weinberg E.O., Massari P., Gibson F.C., 3rd, Wetzler L.M., Morgan E.F., et al. Macrophage-specific TLR2 signaling mediates pathogen-induced TNF-dependent inflammatory oral bone loss. J Immunol. 2013;190:1148–1157. doi: 10.4049/jimmunol.1202511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kim P.D., Xia-Juan X., Crump K.E., Abe T., Hajishengallis G., Sahingur S.E. Toll-Like Receptor 9-Mediated Inflammation Triggers Alveolar Bone Loss in Experimental Murine Periodontitis. Infect Immun. 2015;83:2992–3002. doi: 10.1128/IAI.00424-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Hajishengallis G., Wang M., Liang S. Induction of distinct TLR2-mediated proinflammatory and proadhesive signaling pathways in response to Porphyromonas gingivalis fimbriae. J Immunol. 2009;182:6690–6696. doi: 10.4049/jimmunol.0900524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Wang M., Shakhatreh M.A., James D., Liang S., Nishiyama S., Yoshimura F., et al. Fimbrial proteins of porphyromonas gingivalis mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. J Immunol. 2007;179:2349–2358. doi: 10.4049/jimmunol.179.4.2349. [DOI] [PubMed] [Google Scholar]
  • 77.Hajishengallis G., Shakhatreh M.A., Wang M., Liang S. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo. J Immunol. 2007;179:2359–2367. doi: 10.4049/jimmunol.179.4.2359. [DOI] [PubMed] [Google Scholar]
  • 78.Shimada E., Kataoka H., Miyazawa Y., Yamamoto M., Igarashi T. Lipoproteins of Actinomyces viscosus induce inflammatory responses through TLR2 in human gingival epithelial cells and macrophages. Microbes Infect. 2012;14:916–921. doi: 10.1016/j.micinf.2012.04.015. [DOI] [PubMed] [Google Scholar]
  • 79.Zhou Q., Desta T., Fenton M., Graves D.T., Amar S. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun. 2005;73:935–943. doi: 10.1128/IAI.73.2.935-943.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Nativel B., Couret D., Giraud P., Meilhac O., d'Hellencourt C.L., Viranaicken W., et al. Porphyromonas gingivalis lipopolysaccharides act exclusively through TLR4 with a resilience between mouse and human. Sci Rep. 2017;7:15789. doi: 10.1038/s41598-017-16190-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Park O.J., Cho M.K., Yun C.H., Han S.H. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans induces the expression of chemokines MCP-1, MIP-1alpha, and IP-10 via similar but distinct signaling pathways in murine macrophages. Immunobiology. 2015;220:1067–1074. doi: 10.1016/j.imbio.2015.05.008. [DOI] [PubMed] [Google Scholar]
  • 82.Tanabe S.I., Grenier D. Macrophage tolerance response to Aggregatibacter actinomycetemcomitans lipopolysaccharide induces differential regulation of tumor necrosis factor-alpha, interleukin-1 beta and matrix metalloproteinase 9 secretion. J Periodontal Res. 2008;43:372–377. doi: 10.1111/j.1600-0765.2007.01049.x. [DOI] [PubMed] [Google Scholar]
  • 83.Hussain Q.A., McKay I.J., Gonzales-Marin C., Allaker R.P. Detection of adrenomedullin and nitric oxide in different forms of periodontal disease. J Periodontal Res. 2016;51:16–25. doi: 10.1111/jre.12273. [DOI] [PubMed] [Google Scholar]
  • 84.Pudla M., Srisatjaluk R., Utaisincharoen P. Induction of inducible nitric oxide synthase (iNOS) in Porphyromonas gingivalis LPS-treated mouse macrophage cell line (RAW264.7) requires Toll-like receptor 9. Inflamm Res. 2018;67:723–726. doi: 10.1007/s00011-018-1168-1. [DOI] [PubMed] [Google Scholar]
  • 85.Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–426. doi: 10.1016/s1097-2765(02)00599-3. [DOI] [PubMed] [Google Scholar]
  • 86.Srinivasula S.M., Poyet J.L., Razmara M., Datta P., Zhang Z., Alnemri E.S. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem. 2002;277:21119–21122. doi: 10.1074/jbc.C200179200. [DOI] [PubMed] [Google Scholar]
  • 87.Shenker B.J., Ojcius D.M., Walker L.P., Zekavat A., Scuron M.D., Boesze-Battaglia K. Aggregatibacter actinomycetemcomitans cytolethal distending toxin activates the NLRP3 inflammasome in human macrophages, leading to the release of proinflammatory cytokines. Infect Immun. 2015;83:1487–1496. doi: 10.1128/IAI.03132-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Shi J., Zhao Y., Wang K., Shi X., Wang Y., Huang H., et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660–665. doi: 10.1038/nature15514. [DOI] [PubMed] [Google Scholar]
  • 89.Chen Y., Yang Q., Lv C., Chen Y., Zhao W., Li W., et al. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation. Cell Prolif. 2021;54 doi: 10.1111/cpr.12973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Yamaguchi Y., Kurita-Ochiai T., Kobayashi R., Suzuki T., Ando T. Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res. 2017;66:59–65. doi: 10.1007/s00011-016-0992-4. [DOI] [PubMed] [Google Scholar]
  • 91.Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–678. doi: 10.1038/nature11729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Zang Y., Song J.H., Oh S.H., Kim J.W., Lee M.N., Piao X., et al. Targeting NLRP3 Inflammasome Reduces Age-Related Experimental Alveolar Bone Loss. J Dent Res. 2020;99:1287–1295. doi: 10.1177/0022034520933533. [DOI] [PubMed] [Google Scholar]
  • 93.Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–518. doi: 10.1038/nature07725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Ru H., Ni X., Zhao L., Crowley C., Ding W., Hung L.W., et al. Structural basis for termination of AIM2-mediated signaling by p202. Cell Res. 2013;23 doi: 10.1038/cr.2013.52. 855-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Kim S., Park M.H., Song Y.R., Na H.S., Chung J. Aggregatibacter actinomycetemcomitans-Induced AIM2 Inflammasome Activation Is Suppressed by Xylitol in Differentiated THP-1 Macrophages. J Periodo. 2016;87:e116–e126. doi: 10.1902/jop.2016.150477. [DOI] [PubMed] [Google Scholar]
  • 96.Park E., Na H.S., Song Y.R., Shin S.Y., Kim Y.M., Chung J. Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection. Infect Immun. 2014;82:112–123. doi: 10.1128/IAI.00862-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Cheng R., Wu Z., Li M., Shao M., Hu T. Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review. Int J Oral Sci. 2020;12:2. doi: 10.1038/s41368-019-0068-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Galluzzi L., Bravo-San Pedro J.M., Vitale I., Aaronson S.A., Abrams J.M., Adam D., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015;22:58–73. doi: 10.1038/cdd.2014.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Malireddi R.K.S., Gurung P., Kesavardhana S., Samir P., Burton A., Mummareddy H., et al. Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease. J Exp Med. 2020:217. doi: 10.1084/jem.20191644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Li Z., Zheng Q., Xue X., Shi X., Zhou Y., Da F., et al. Pyroptosis of Salmonella Typhimurium-infected macrophages was suppressed and elimination of intracellular bacteria from macrophages was promoted by blocking QseC. Sci Rep. 2016;6:37447. doi: 10.1038/srep37447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Miao E.A., Leaf I.A., Treuting P.M., Mao D.P., Dors M., Sarkar A., et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11:1136–1142. doi: 10.1038/ni.1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.He D., Li X., Zhang F., Wang C., Liu Y., Bhawal U.K., et al. Dec2 inhibits macrophage pyroptosis to promote periodontal homeostasis. J Periodontal Implant Sci. 2022;52:28–38. doi: 10.5051/jpis.2101380069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Zhou X., Wang Q., Nie L., Zhang P., Zhao P., Yuan Q., et al. Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis. Arch Oral Biol. 2020;116 doi: 10.1016/j.archoralbio.2020.104763. [DOI] [PubMed] [Google Scholar]
  • 104.Li C., Yin W., Yu N., Zhang D., Zhao H., Liu J., et al. miR-155 promotes macrophage pyroptosis induced by Porphyromonas gingivalis through regulating the NLRP3 inflammasome. Oral Dis. 2019;25:2030–2039. doi: 10.1111/odi.13198. [DOI] [PubMed] [Google Scholar]
  • 105.Taabazuing C.Y., Okondo M.C., Bachovchin D.A. Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages. Cell Chem Biol. 2017;24 doi: 10.1016/j.chembiol.2017.03.009. 507-14 e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Pasparakis M., Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517:311–320. doi: 10.1038/nature14191. [DOI] [PubMed] [Google Scholar]
  • 107.He S., Liang Y., Shao F., Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci USA. 2011;108:20054–20059. doi: 10.1073/pnas.1116302108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.McComb S., Cessford E., Alturki N.A., Joseph J., Shutinoski B., Startek J.B., et al. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages. Proc Natl Acad Sci USA. 2014;111:E3206–E3213. doi: 10.1073/pnas.1407068111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Chen X., Li W., Ren J., Huang D., He W.-T., Song Y., et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res. 2014;24:105–121. doi: 10.1038/cr.2013.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Ke X., Lei L., Li H., Li H., Yan F. Manipulation of necroptosis by Porphyromonas gingivalis in periodontitis development. Mol Immunol. 2016:77. doi: 10.1016/j.molimm.2016.07.010. [DOI] [PubMed] [Google Scholar]
  • 111.Yang Y., Wang L., Zhang H., Luo L. Mixed lineage kinase domain-like pseudokinase-mediated necroptosis aggravates periodontitis progression. J Mol Med. 2022;100:77–86. doi: 10.1007/s00109-021-02126-7. [DOI] [PubMed] [Google Scholar]
  • 112.Yamaguchi H., Maruyama T., Urade Y., Nagata S. Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells. eLife. 2014;3 doi: 10.7554/eLife.02172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Wallach D., Kovalenko A. Keeping inflammation at bay. eLife. 2014;3 doi: 10.7554/eLife.02583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813–822. doi: 10.1038/nri1943. [DOI] [PubMed] [Google Scholar]
  • 115.Aliprantis A.O., Yang R.B., Weiss D.S., Godowski P., Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO. 2000;19:3325–3336. doi: 10.1093/emboj/19.13.3325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Peterson L.W., Philip N.H., Dillon C.P., Bertin J., Gough P.J., Green D.R., et al. Cell-extrinsic TNF collaborates with TRIF signaling to promote yersinia-induced apoptosis. J Immunol. 2016;197:4110–4117. doi: 10.4049/jimmunol.1601294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Kato S., Muro M., Akifusa S., Hanada N., Semba I., Fujii T., et al. Evidence for apoptosis of murine macrophages by Actinobacillus actinomycetemcomitans infection. Infect Immun. 1995;63:3914–3919. doi: 10.1128/iai.63.10.3914-3919.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Ihalin R., Eneslatt K., Asikainen S. Peptidoglycan-associated lipoprotein of Aggregatibacter actinomycetemcomitans induces apoptosis and production of proinflammatory cytokines via TLR2 in murine macrophages RAW 264.7 in vitro. J Oral Microbiol. 2018;10 doi: 10.1080/20002297.2018.1442079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Xue Y., Xiao H., Guo S., Xu B., Liao Y., Wu Y., et al. Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis. 2018;9:355. doi: 10.1038/s41419-018-0389-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Gawrisch K. Mycobacterium tuberculosis enters macrophages with aid from a bacterial lipid. Proc Natl Acad Sci USA. 2019;116:25372–25373. doi: 10.1073/pnas.1918900116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Chen M., Gan H., Remold H.G. A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol. 2006;176:3707–3716. doi: 10.4049/jimmunol.176.6.3707. [DOI] [PubMed] [Google Scholar]
  • 122.Lee J., Hartman M., Kornfeld H. Macrophage apoptosis in tuberculosis. Yonsei Med J. 2009;50:1–11. doi: 10.3349/ymj.2009.50.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Hollenstein D.M., Kraft C. Autophagosomes are formed at a distinct cellular structure. Curr Opin Cell Biol. 2020;65:50–57. doi: 10.1016/j.ceb.2020.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Yin S., Cao W. Toll-Like receptor signaling induces Nrf2 pathway activation through p62-triggered Keap1 degradation. Mol Cell Biol. 2015;35:2673–2683. doi: 10.1128/MCB.00105-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Fujita K., Maeda D., Xiao Q., Srinivasula S.M. Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation. Proc Natl Acad Sci USA. 2011;108:1427–1432. doi: 10.1073/pnas.1014156108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Xu Y., Jagannath C., Liu X.D., Sharafkhaneh A., Kolodziejska K.E., Eissa N.T. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity. 2007;27:135–144. doi: 10.1016/j.immuni.2007.05.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Park M.H., Jeong S.Y., Na H.S., Chung J. Porphyromonas gingivalis induces autophagy in THP-1-derived macrophages. Mol Oral Microbiol. 2017;32:48–59. doi: 10.1111/omi.12153. [DOI] [PubMed] [Google Scholar]
  • 128.Schroder K., Tschopp J. The inflammasomes. Cell. 2010;140:821–832. doi: 10.1016/j.cell.2010.01.040. [DOI] [PubMed] [Google Scholar]
  • 129.Nakahira K., Haspel J.A., Rathinam V.A., Lee S.J., Dolinay T., Lam H.C., et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222–230. doi: 10.1038/ni.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Shi C.S., Shenderov K., Huang N.N., Kabat J., Abu-Asab M., Fitzgerald K.A., et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012;13:255–263. doi: 10.1038/ni.2215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Zhuang Z., Yoshizawa-Smith S., Glowacki A., Maltos K., Pacheco C., Shehabeldin M., et al. Induction of M2 macrophages prevents bone loss in murine periodontitis models. J Dent Res. 2019;98:200–208. doi: 10.1177/0022034518805984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Fine D.H., Markowitz K., Fairlie K., Tischio-Bereski D., Ferrandiz J., Godboley D., et al. Macrophage inflammatory protein-1α shows predictive value as a risk marker for subjects and sites vulnerable to bone loss in a longitudinal model of aggressive periodontitis. PLoS One. 2014;9 doi: 10.1371/journal.pone.0098541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Ortiz-García Y.M., García-Iglesias T., Morales-Velazquez G., Lazalde-Ramos B.P., Zúñiga-González G.M., Ortiz-García R.G., et al. Macrophage migration inhibitory factor levels in gingival crevicular fluid, saliva, and serum of chronic periodontitis patients. Biomed Res Int. 2019;2019 doi: 10.1155/2019/7850392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Rath-Deschner B., Memmert S., Damanaki A., Nokhbehsaim M., Eick S., Cirelli J.A., et al. CXCL1, CCL2, and CCL5 modulation by microbial and biomechanical signals in periodontal cells and tissues-in vitro and in vivo studies. Clin Oral Investig. 2020;24:3661–3670. doi: 10.1007/s00784-020-03244-1. [DOI] [PubMed] [Google Scholar]
  • 135.Murakami Y., Yuhara K., Takada N., Arai T., Tsuda S., Takamatsu S., et al. Effect of melatonin on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis. In Vivo. 2011;25:641–647. [PubMed] [Google Scholar]
  • 136.Noguchi K., Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2000. 2007;43:85–101. doi: 10.1111/j.1600-0757.2006.00170.x. [DOI] [PubMed] [Google Scholar]
  • 137.Yarilina A., Park-Min K.-H., Antoniv T., Hu X., Ivashkiv L.B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 2008;9:378–387. doi: 10.1038/ni1576. [DOI] [PubMed] [Google Scholar]
  • 138.Gümüş P., Nizam N., Lappin D.F., Buduneli N. Saliva and serum levels of B-cell activating factors and tumor necrosis factor-α in patients with periodontitis. J Periodotol. 2014;85:270–280. doi: 10.1902/jop.2013.130117. [DOI] [PubMed] [Google Scholar]
  • 139.Luo G., Li F., Li X., Wang Z.-G., Zhang B. TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway. Mol Med Rep. 2018;17:6605–6611. doi: 10.3892/mmr.2018.8698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Böhm C., Derer A., Axmann R., Hillienhoff U., Zaiss M.M., Luther J., et al. RSK2 protects mice against TNF-induced bone loss. J Cell Sci. 2012;125:2160–2171. doi: 10.1242/jcs.096008. [DOI] [PubMed] [Google Scholar]
  • 141.Boyce B.F., Schwarz E.M., Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol. 2006;18:427–432. doi: 10.1097/01.bor.0000231913.32364.32. [DOI] [PubMed] [Google Scholar]
  • 142.Nile C.J., Sherrabeh S., Ramage G., Lappin D.F. Comparison of circulating tumour necrosis factor superfamily cytokines in periodontitis patients undergoing supportive therapy: a case-controlled cross-sectional study comparing smokers and non-smokers in health and disease. J Clin Periodontol. 2013;40:875–882. doi: 10.1111/jcpe.12134. [DOI] [PubMed] [Google Scholar]
  • 143.Bostanci N., Ilgenli T., Emingil G., Afacan B., Han B., Töz H., et al. Differential expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res. 2007;42:287–293. doi: 10.1111/j.1600-0765.2006.00946.x. [DOI] [PubMed] [Google Scholar]
  • 144.Jin Q., Cirelli J.A., Park C.H., Sugai J.V., Taba M., Jr., Kostenuik P.J., et al. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol. 2007;78:1300–1308. doi: 10.1902/jop.2007.070073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145.Assuma R., Oates T., Cochran D., Amar S., Graves D.T. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol. 1998;160:403–409. [PubMed] [Google Scholar]
  • 146.Kubota T., Itagaki M., Hoshino C., Nagata M., Morozumi T., Kobayashi T., et al. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue. J Periodontol. 2008;79:166–173. doi: 10.1902/jop.2008.070159. [DOI] [PubMed] [Google Scholar]
  • 147.Grenier D., Grignon L. Response of human macrophage-like cells to stimulation by Fusobacterium nucleatum ssp. nucleatum lipopolysaccharide. Oral Microbiol Immunol. 2006;21:190–196. doi: 10.1111/j.1399-302X.2006.00278.x. [DOI] [PubMed] [Google Scholar]
  • 148.Tanabe S.I., Bodet C., Grenier D. Treponema denticola peptidoglycan induces the production of inflammatory mediators and matrix metalloproteinase 9 in macrophage-like cells. J Periodontal Res. 2009;44:503–510. doi: 10.1111/j.1600-0765.2008.01141.x. [DOI] [PubMed] [Google Scholar]
  • 149.Victor D.J., Subramanian S., Gnana P.P., Kolagani S.P. Assessment of matrix metalloproteinases-8 and -9 in gingival crevicular fluid of smokers and non-smokers with chronic periodontitis using ELISA. J Int Oral Health: JIOH. 2014;6:67–71. [PMC free article] [PubMed] [Google Scholar]
  • 150.Kiili M., Cox S.W., Chen H.Y., Wahlgren J., Maisi P., Eley B.M., et al. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. J Clin Periodontol. 2002;29:224–232. doi: 10.1034/j.1600-051x.2002.290308.x. [DOI] [PubMed] [Google Scholar]
  • 151.Hill P.A., Docherty A.J., Bottomley K.M., O'Connell J.P., Morphy J.R., Reynolds J.J., et al. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J. 1995;308(Pt 1):167–175. doi: 10.1042/bj3080167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Hernández Ríos M., Sorsa T., Obregón F., Tervahartiala T., Valenzuela M.A. Pozo P, et al. Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade. J Clin Periodontol. 2009;36:1011–1017. doi: 10.1111/j.1600-051X.2009.01488.x. [DOI] [PubMed] [Google Scholar]
  • 153.Hernández M., Dutzan N., García-Sesnich J., Abusleme L., Dezerega A., Silva N., et al. Host-pathogen interactions in progressive chronic periodontitis. J Dent Res. 2011;90:1164–1170. doi: 10.1177/0022034511401405. [DOI] [PubMed] [Google Scholar]
  • 154.Chen Y., Wang H., Yang Q., Zhao W., Chen Y., Ni Q., et al. Single-cell RNA landscape of the osteoimmunology microenvironment in periodontitis: Theranostics. 2022 Jan 1;12(3):1074–96. doi: 10.7150/thno.65694. eCollection 2022. [DOI] [PMC free article] [PubMed]
  • 155.Knittel T., Mehde M., Kobold D., Saile B., Dinter C., Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol. 1999;30:48–60. doi: 10.1016/s0168-8278(99)80007-5. [DOI] [PubMed] [Google Scholar]
  • 156.Pellicoro A., Aucott R.L., Ramachandran P., Robson A.J., Fallowfield J.A., Snowdon V.K., et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology. 2012;55:1965–1975. doi: 10.1002/hep.25567. [DOI] [PubMed] [Google Scholar]
  • 157.Fallowfield J.A., Mizuno M., Kendall T.J., Constandinou C.M., Benyon R.C., Duffield J.S., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178:5288–5295. doi: 10.4049/jimmunol.178.8.5288. [DOI] [PubMed] [Google Scholar]
  • 158.Lam A., Prabhu R., Gross C.M., Riesenberg L.A., Singh V., Aggarwal S. Role of apoptosis and autophagy in tuberculosis. Am J Physiol Lung Cell Mol Physiol. 2017;313 doi: 10.1152/ajplung.00162.2017. L218-l29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Gupta A., Galinski M.R., Voit E.O. Dynamic control balancing cell proliferation and inflammation is crucial for an effective immune response to malaria. Front Mol Biosci. 2021;8 doi: 10.3389/fmolb.2021.800721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Sima C., Viniegra A., Glogauer M. Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis. J Leukoc Biol. 2019;105:473–487. doi: 10.1002/JLB.1RU0818-310R. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161.Lucas T., Waisman A., Ranjan R., Roes J., Krieg T., Müller W., et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol. 2010;184:3964–3977. doi: 10.4049/jimmunol.0903356. [DOI] [PubMed] [Google Scholar]
  • 162.Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–1358. doi: 10.1056/NEJM200005043421807. [DOI] [PubMed] [Google Scholar]
  • 163.Li W., Liu T., Wu L., Chen C., Jia Z., Bai X., et al. Blocking the function of inflammatory cytokines and mediators by using IL-10 and TGF-β: a potential biological immunotherapy for intervertebral disc degeneration in a beagle model. Int J Mol Sci. 2014;15:17270–17283. doi: 10.3390/ijms151017270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164.Langermans J.A., Nibbering P.H., Van Vuren-Van Der Hulst M.E., Van Furth R. Transforming growth factor-beta suppresses interferon-gamma-induced toxoplasmastatic activity in murine macrophages by inhibition of tumour necrosis factor-alpha production. Parasite Immunol. 2001;23:169–175. doi: 10.1046/j.1365-3024.2001.00371.x. [DOI] [PubMed] [Google Scholar]
  • 165.Randow F., Syrbe U., Meisel C., Krausch D., Zuckermann H., Platzer C., et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med. 1995;181:1887–1892. doi: 10.1084/jem.181.5.1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Rani R., Smulian A.G., Greaves D.R., Hogan S.P., Herbert D.B.R. TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur J Immunol. 2011;41:2000–2009. doi: 10.1002/eji.201041135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167.Khalil N., Whitman C., Zuo L., Danielpour D., Greenberg A. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest. 1993;92:1812–1818. doi: 10.1172/JCI116771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36–46. doi: 10.1038/nri2675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Frutkin A.D., Otsuka G., Stempien-Otero A., Sesti C., Du L., Jaffe M., et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009;29:1251–1257. doi: 10.1161/ATVBAHA.109.186593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Steinmetz O., Hoch S., Avniel-Polak S., Gavish K., Eli-Berchoer L., Wilensky A., et al. CX3CR1hi monocyte/macrophages support bacterial survival and experimental infection-driven bone resorption. J Infect Dis. 2016;213:1505–1515. doi: 10.1093/infdis/jiv763. [DOI] [PubMed] [Google Scholar]
  • 171.Burgess M., Wicks K., Gardasevic M., Mace K.A. Cx3CR1 expression identifies distinct macrophage populations that contribute differentially to inflammation and repair. ImmunoHorizons. 2019;3:262–273. doi: 10.4049/immunohorizons.1900038. [DOI] [PubMed] [Google Scholar]
  • 172.Medina-Contreras O., Geem D., Laur O., Williams I.R., Lira S.A., Nusrat A., et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011;121:4787–4795. doi: 10.1172/JCI59150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173.Sun L., Girnary M., Wang L., Jiao Y., Zeng E., Mercer K., et al. IL-10 Dampens an IL-17-mediated periodontitis-associated inflammatory network. J Immunol. 2020;204:2177–2191. doi: 10.4049/jimmunol.1900532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.Ip W.K.E., Hoshi N., Shouval D.S., Snapper S., Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513–519. doi: 10.1126/science.aal3535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Hu G., Su Y., Kang B.H., Fan Z., Dong T., Brown D.R., et al. High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. Nat Commun. 2021;12:773. doi: 10.1038/s41467-021-21066-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Garlet G.P., Giannobile W.V. Macrophages: the bridge between inflammation resolution and tissue repair? J Dent Res. 2018;97:1079–1081. doi: 10.1177/0022034518785857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Kim H., Wang S.Y., Kwak G., Yang Y., Kwon I.C., Kim S.H. Exosome-guided Phenotypic Switch of M1 to M2 macrophages for cutaneous wound healing. Adv Sci. 2019;6 doi: 10.1002/advs.201900513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.O'Brien EM, Spiller KL. Pro-inflammatory polarization primes Macrophages to transition into a distinct M2-like phenotype in response to IL-4. J Leukoc Biol.; 2021. [DOI] [PMC free article] [PubMed]
  • 179.Yu T., Zhao L., Huang X., Ma C., Wang Y., Zhang J., et al. Enhanced activity of the macrophage M1/M2 phenotypes and phenotypic switch to M1 in Periodontal Infection. J Periodontol. 2016;87:1092–1102. doi: 10.1902/jop.2016.160081. [DOI] [PubMed] [Google Scholar]
  • 180.Viniegra A., Goldberg H., Cil C., Fine N., Sheikh Z., Galli M., et al. Resolving macrophages counter osteolysis by anabolic actions on bone cells. J Dent Res. 2018;97:1160–1169. doi: 10.1177/0022034518777973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Yang J., Zhu Y., Duan D., Wang P., Xin Y., Bai L., et al. Enhanced activity of macrophage M1/M2 phenotypes in periodontitis. Arch Oral Biol. 2018;96:234–242. doi: 10.1016/j.archoralbio.2017.03.006. [DOI] [PubMed] [Google Scholar]
  • 182.Matusiewicz M., Neubauer K., Mierzchala-Pasierb M., Gamian A., Krzystek-Korpacka M. Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014 doi: 10.1155/2014/643645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 183.Miao Y., He L., Qi X., Lin X. Injecting immunosuppressive M2 macrophages alleviates the symptoms of periodontitis in mice. Front Mol Biosci. 2020;7 doi: 10.3389/fmolb.2020.603817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Liu J., Chen B., Bao J., Zhang Y., Lei L., Yan F. Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration. Stem Cell Res Ther. 2019;10:320. doi: 10.1186/s13287-019-1409-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185.Wang R., Ji Q., Meng C., Liu H., Fan C., Lipkind S., et al. Role of gingival mesenchymal stem cell exosomes in macrophage polarization under inflammatory conditions. Int Immunopharmacol. 2020;81 doi: 10.1016/j.intimp.2019.106030. [DOI] [PubMed] [Google Scholar]
  • 186.Maekawa T., Krauss J.L., Abe T., Jotwani R., Triantafilou M., Triantafilou K., et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. 2014;15:768–778. doi: 10.1016/j.chom.2014.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187.Makkawi H., Hoch S., Burns E., Hosur K., Hajishengallis G., Kirschning C.J., et al. Porphyromonas gingivalis Stimulates TLR2-PI3K signaling to escape immune clearance and induce bone resorption independently of MyD88. Front Cell Infect Microbiol. 2017;7:359. doi: 10.3389/fcimb.2017.00359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188.Chukkapalli S.S., Velsko I.M., Rivera-Kweh M.F., Larjava H., Lucas A.R., Kesavalu L. Global TLR2 and 4 deficiency in mice impacts bone resorption, inflammatory markers and atherosclerosis to polymicrobial infection. Mol Oral Microbiol. 2017;32:211–225. doi: 10.1111/omi.12165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.Hajishengallis G. Toll gates to periodontal host modulation and vaccine therapy. Periodontol 2000. 2009;51:181–207. doi: 10.1111/j.1600-0757.2009.00304.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190.Hajishengallis G., Wang M., Liang S., Triantafilou M., Triantafilou K. Pathogen induction of CXCR4/TLR2 cross-talk impairs host defense function. Proc Natl Acad Sci USA. 2008;105:13532–13537. doi: 10.1073/pnas.0803852105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191.Yaw A.C.K., Chan E.W.L., Yap J.K.Y., Mai C.W. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation. J Cancer Res Clin Oncol. 2020;146:2219–2229. doi: 10.1007/s00432-020-03274-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192.Yang G., Lee H.E., Moon S.J., Ko K.M., Koh J.H., Seok J.K., et al. Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis. Arthritis Rheumatol. 2020;72:1192–1202. doi: 10.1002/art.41245. [DOI] [PubMed] [Google Scholar]
  • 193.Kawahara Y., Kaneko T., Yoshinaga Y., Arita Y., Nakamura K., Koga C., et al. Effects of sulfonylureas on periodontopathic bacteria-induced inflammation. J Dent Res. 2020;99:830–838. doi: 10.1177/0022034520913250. [DOI] [PubMed] [Google Scholar]
  • 194.Ginhoux F., Schultze J.L., Murray P.J., Ochando J., Biswas S.K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17:34–40. doi: 10.1038/ni.3324. [DOI] [PubMed] [Google Scholar]
  • 195.Nahrendorf M., Swirski F.K. Abandoning M1/M2 for a network model of macrophage function. Circ Res. 2016;119:414–417. doi: 10.1161/CIRCRESAHA.116.309194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196.Lavin Y., Winter D., Blecher-Gonen R., David E., Keren-Shaul H., Merad M., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014;159:1312–1326. doi: 10.1016/j.cell.2014.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 197.Xue J., Schmidt S.V., Sander J., Draffehn A., Krebs W., Quester I., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40:274–288. doi: 10.1016/j.immuni.2014.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Japanese Dental Science Review are provided here courtesy of Elsevier

RESOURCES